The Trendlines Group's Portfolio Company Seger Surgical Solutions Achieves Successful Human Trials of Laparoscopic Bowel Closure Device

- *Three Successful First-in-Human Cases Completed in El Salvador*

- *Founded and incubated by Trendlines, Seger's **SEGER IDEA™** device enables surgeons to align, close, and staple the common enterotomy entirely inside the body, eliminating complex hand-sewn suturing and the traditional extracorporeal method.*

Misgav, Israel – 17 March 2026 – The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY), an investment group focused on agrifood and medtech innovation, announced that its portfolio company Seger Surgical Solutions Ltd. ("**Seger**") announced the successful completion of three first-in-human cases in a clinical trial for its proprietary SEGER IDEA™ laparoscopic bowel closure device. The procedures, conducted at Zacamil National Hospital in El Salvador, represent a pivotal milestone in the company's mission to standardize 100% Intracorporeal Anastomosis ("**IA**"), a technique that keeps the entire bowel closure procedure inside the body.

Transforming Laparoscopic Surgery

The SEGER IDEA device enables surgeons to align, close, and staple the common enterotomy quickly and securely entirely inside the body, eliminating the need for complex hand-sewn suturing or the traditional "extracorporeal" method, which requires larger incisions and lifting the bowel outside the abdominal cavity. The El Salvador trial was designed to demonstrate the safety and efficacy of this approach.

Key Clinical Highlights

- **Three Successful Cases:** All three procedures were completed with ease, achieving 100% intracorporeal results.
- **Reduced Procedure Time:** Bowel closures were performed in under 2 minutes, compared to the typical 15–20 minutes required for manual laparoscopic suturing.
- **Enhanced Patient Recovery:** Smaller incisions and reduced tissue handling aim to lower postoperative pain and risk of incisional hernias.

"We have made history today! The success of our first-in-human cases in El Salvador validates our vision for the future of surgery," said Seger's CEO, Shahar Millis. "We are proving that 100% IA is no longer a 'high-wire act' reserved for a few, but a reachable standard for many."

"This milestone surgery highlights the quality and potential of companies within the Trendlines portfolio," said Haim Brosh, CEO of Trendlines. "Supporting innovations that deliver real impact in healthcare is at the core of what we do."

-The End-

About The Trendlines Group Ltd.
The Trendlines Group (SGX: 42T; OTCQX: TRNLY) invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term value for shareholders.

---

*This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Investor Contact Information
Israel:
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore:
Kamal Samuel, Financial PR
kamal@financialpr.com.sg
Rishika Tiwari, Financial PR
rishika@financialpr.com.sg
Tel: +65.6438.2990